NewsBenzingaKalaris Therapeutics: el BPA del tercer trimestre de $(0.46) supera la estimación de $(0.51) Kalaris Therapeutics: el BPA del tercer trimestre de $(0.46) supera la estimación de $(0.51) Benzinga 2026.11.10 18:41 (GMT+0) Open on Benzinga Other news Citigroup Maintains Buy on Kodiak AI, Lowers Price Target to $7 Swoosh and a Miss: Nike Investor Day Leaves Wall Street Cold-Footed Wall Street Says the AI Trade Is Over — ETF Investors Aren’t Acting Like It Citigroup Maintains Neutral on Westlake, Lowers Price Target to $65 Citigroup Maintains Neutral on LyondellBasell Industries, Lowers Price Target to $66 Caterpillar's 'Best-In-Class' Construction Business Is Getting Overlooked, Analyst Says